EGFR and non-small cell lung carcinoma: Targeted therapy with tyrosine kinase inhibitors (TKIs), which suppress EGFR tyrosine kinase activity and its downstream signaling pathways, is the standard treatment for NSCLC patients harboring these mutations 3.